Literature DB >> 822114

Protection against group B meningococcal disease. I. Comparison of group-specific and type-specific protection in the chick embryo model.

C E Frasch, L Parkes, R M McNelis, E C Gotschlich.   

Abstract

Protection against group B meningococcal infection was examined using the chick embryo. 12-day-old embryos were challenged intravenously with various meningococcal strains. The chick embryo has an active reticuloendothelial system but lacks functional complement. In this model we found that protection against group B infection was primarily group specific. The group B polysaccharide antibody is an effective opsonin, but is a very poor bactericidal antibody. In contrast, the serotype antibody was bactericidal but only slightly protective in the chick embryo where protection is primarily phagocytic in nature. The group-specific and type-specific antibodies are strongly synergistic. Minute amounts of group B polysaccharide antibody caused a very significant increase in the protective effects of the serotype antibody.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 822114      PMCID: PMC2190389          DOI: 10.1084/jem.144.2.319

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  Antigenic specificity of bactericidal antibodies in antisera to Neisseria meningitidis.

Authors:  D L Kasper; J L Winkelhake; B L Brandt; M S Artenstein
Journal:  J Infect Dis       Date:  1973-04       Impact factor: 5.226

2.  Adsorbents for affinity chromatography. Use of N-hydroxysuccinimide esters of agarose.

Authors:  P Cuatrecasas; I Parikh
Journal:  Biochemistry       Date:  1972-06-06       Impact factor: 3.162

3.  The chick embryo neutralization test in the assay of meningococcal antibody. 1. Infection of the embryo with Neisseria meningitidis.

Authors:  K Ueda; B B Diena; L Greenberg
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

4.  Trends in meningococcal disease, 1974.

Authors:  J A Jacobson; R E Weaver; C Thornsberry
Journal:  J Infect Dis       Date:  1975-10       Impact factor: 5.226

Review 5.  Development of polysaccharide vaccines for the prevention of meningococcal diseases.

Authors:  E C Gotschlich
Journal:  Monogr Allergy       Date:  1975

6.  Attempts to establish Neisseria meningitidis in gnotobiotic animals.

Authors:  T Midtvedt; K Jyssum
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1971

7.  Epidemiologic studies of serotype antigens common to groups B and C Neisseria meningitidis.

Authors:  R S Munford; C M Patton; G W Gorman
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

8.  Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers.

Authors:  E C Gotschlich; I Goldschneider; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

9.  EXPERIMENTAL MENINGOCOCCUS INFECTION OF THE CHICK EMBRYO.

Authors:  G J Buddingh; A D Polk
Journal:  J Exp Med       Date:  1939-10-31       Impact factor: 14.307

10.  THE PATHOGENESIS OF MENINGOCOCCUS MENINGITIS IN THE CHICK EMBRYO.

Authors:  G J Buddingh; A D Polk
Journal:  J Exp Med       Date:  1939-10-31       Impact factor: 14.307

View more
  19 in total

1.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

Review 2.  The meningococcus and mechanisms of pathogenicity.

Authors:  I W DeVoe
Journal:  Microbiol Rev       Date:  1982-06

3.  Human opsonins to meningococci after vaccination.

Authors:  A Halstensen; B Haneberg; L O Frøholm; V Lehmann; C E Frasch; C O Solberg
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

4.  Protection against group B Neisseria meningitidis disease: effect of serogroup B polysaccharide and polymyxin B on immunogenicity of serotype protein preparations.

Authors:  M S Peppler; C E Frasch
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

5.  A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.

Authors:  Kenneth T Mountzouros; Kelly A Belanger; Alan P Howell; Garvin S Bixler; Dace V Madore
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

6.  Chicken embryo model for type III group B beta-hemolytic streptococcal septicemia.

Authors:  J Tieffenberg; L Vogel; R R Kretschmer; D Padnos; S P Gotoff
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

7.  Problems posed by potential gonococcal vaccines viewed from the vantage point of a control agency.

Authors:  J B Robbins
Journal:  Br J Vener Dis       Date:  1977-06

8.  Protection against Escherichia coli K1 infection in newborn rats by antibody to K1 capsular polysaccharide antigen.

Authors:  R Bortolussi; P Ferrier
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

9.  Immunization with major outer membrane proteins in experimental salmonellosis of mice.

Authors:  N Kuusi; M Nurminen; H Saxen; M Valtonen; P H Mäkelä
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

10.  Immune responses in mice to different noncovalent complexes of meningococcal B polysaccharide and outer membrane proteins.

Authors:  M R Lifely; Z Wang
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.